Co-Authors
This is a "connection" page, showing publications co-authored by AMY B HEIMBERGER and MARTA PENAS-PRADO.
Connection Strength
0.617
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.180
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.180
-
Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018 Sep; 139(3):713-720.
Score: 0.158
-
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.
Score: 0.049
-
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073.
Score: 0.049